An interobserver reproducibility analysis of Ki67 visual assessment in breast cancer

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Shui, Ruohong ^a,b   Yu, Baohua ^a,b   Bi, Rui ^a,b   Yang, Fei ^a,b   Yang, Wentao ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; AVERAGE SCORE METHOD; BREAST CANCER; BREAST CARCINOMA; BREAST SURGERY; CANCER GRADING; COLLOID CARCINOMA; CONTROLLED STUDY; FEMALE; HOT SPOT SCORE METHOD; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PATHOLOGIST; REPRODUCIBILITY; SCORING SYSTEM; TUMOR CELL; TUMOR INVASION; BREAST TUMOR; CONFIDENCE INTERVAL; METABOLISM; MIDDLE AGED; OBSERVER VARIATION; PATHOLOGY; STAINING; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CONFIDENCE INTERVALS; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM INVASIVENESS; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; STAINING AND LABELING; YOUNG ADULT;

EID: 84928822937     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125131     Document Type: Article

References (20)

1. de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients. Br J Cancer. 2007; 96: 1504-1513. PMID: 17453008
2. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009; 101: 736-750. doi: 10.1093/jnci/djp082 PMID: 19436038
3. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010; 11: 174-183. doi: 10.1016/S1470-2045(09)70262-1 PMID: 20152769
4. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health Recurrence Score in early breast cancer. J Clin Oncol. 2011; 29: 4273-4278. doi: 10.1200/JCO.2010.31.2835 PMID: 21990413
5. Niikura N, Iwamoto T, Masuda S, Kumaki N, Xiaoyan T, Shirane M, et al. Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer. Cancer Sci. 2012; 103: 1508-1512. doi: 10.1111/j.1349-7006.2012.02319.x PMID: 22537114
6. Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013; 142: 69-80. PMID: 24122389
7. von Minckwitz G, Schmitt WD, Loibl S, Muller BM, Blohmer JU, Sinn BV, et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2013; 19: 4521-4531.
8. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes -dealing with the diversity of Breast Cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22: 1736-1747. doi: 10.1093/annonc/mdr304 PMID: 21709140
9. Jonat W, Arnold N. Is the Ki-67 labelling index ready for clinical use? Ann Oncol. 2011; 22: 500-502. doi: 10.1093/annonc/mdq732 PMID: 21343384
10. Gudlaugsson E, Skaland I, Janssen EA, Smaaland R, Shao Z, Malpica A, et al. Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer. Histopathology. 2012; 61:1134-1144. doi: 10.1111/j.1365-2559. 2012.04329.x PMID: 22963617
11. Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, et al. An International Ki67 Reproducibility Study. J Natl Cancer Inst. 2013; 105: 1897-1906. doi: 10.1093/jnci/djt306 PMID: 24203987
12. Mikami Y, Ueno T, Yoshimura K, Tsuda H, Kurosumi M, Masuda S, et al. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. Cancer Sci. 2013; 104: 1539-1543. doi: 10.1111/cas.12245 PMID: 23905924
13. Vörös A, Csörgo{combining double acute accent} E, Nyári T, Cserni G. An Intra- and Interobserver Reproducibility Analysis of the Ki-67 Proliferation Marker Assessment on Core Biopsies of Breast Cancer Patients and Its Potential Clinical Implications. Pathobiology. 2013; 80: 111-118. doi: 10.1159/000343795 PMID: 23258384
14. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2011; 103:1656-1664. doi: 10.1093/jnci/djr393 PMID: 21960707
15. Fleiss JL, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. Educ Psychol Meas. 1973; 33: 613-619.
16. Laurinavicius A, Plancoulaine B, Laurinaviciene A, Herlin P, Meskauskas R, Baltrusaityte I, et al. A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue. Breast Cancer Research. 2014; 16: R35. PMID: 24708745
17. Hida AI, Oshiro Y, Inoue H, Kawaguchi H, Yamashita N, Moriya T. Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells. Breast Cancer. 2013; doi: 10.1007/s12282-013-0460-8
18. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 2008; 17: 323-334. doi: 10.1016/j.breast.2008.02.002 PMID: 18455396
19. Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One. 2012; 7: e37379. doi: 10.1371/journal.pone.0037379 PMID: 22662150
20. Cserni G, Vörös A, Liepniece-Karele I, Bianchi S, Vezzosi V, Grabau D, et al. Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values. Breast. 2014; 23: 259-263. doi: 10.1016/j.breast.2014.02.003 PMID: 24613255